ALK and non-small cell lung carcinoma: In NSCLC-type adenocancer, two mutations are widely used to direct treatments: an epidermal growth factor receptor- (EGFR-) activating mutation indicating use of gefitinib erlotinib and afatinib [3] and an ALK (anaplastic lymphoma kinase) gene rearrangement, indicating use of critsonitib [4, 5].